**NAFDAC Issues Fresh Warning on Unstable Malaria Medication** In a critical alert, the National Agency for Food and Drug Administration and Control (NAFDAC) has reiterated its stance on the ban on multi-dose anti-malaria suspension, emphasizing the risk of losing efficacy if not used within a short period. This caution comes as the agency seeks to protect Nigerians from the health implications of substandard medication. **Why the Alarm Bells?** Stability studies have shown that when artemether/lumefantrine dry powder for oral suspension is reconstituted, it rapidly loses its potency, rendering it ineffective in treating malaria. This has serious health implications, including the worsening of the condition being treated, increased risk of complications, and in severe cases, even death. **What's the Solution?** NAFDAC has directed manufacturers to switch to safer and more stable alternatives, such as dispersible tablets or powders packaged in sachets for single-dose use. Single-dose formulations prevent the instability issues associated with multi-dose suspensions, ensuring that patients receive the therapeutic effect they need to recover from malaria. **What's Next?** Healthcare professionals and consumers are advised to report any suspected sale of the discontinued products, as well as substandard or falsified medicines and medical devices, to the nearest NAFDAC office or through the agency's toll-free number. This surveillance is crucial in preventing the circulation of ineffective or even toxic medication in the country. In conclusion, NAFDAC's ban on multi-dose anti-malaria suspension is a necessary step in protecting Nigerians from the risks associated with substandard medication. As we navigate the complexities of malaria treatment, it's essential that we prioritize the use of safe and effective medications to prevent the spread of this debilitating disease. By working together, we can ensure that Nigerians have access to quality healthcare and effective treatment for malaria.